SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers.
Jannier S, Kemmel V, Sebastia Sancho C, Chammas A, Sabo AN, Pencreach E, Farace F, Chenard MP, Lhermitte B, Geoerger B, Aerts I, Frappaz D, Leblond P, André N, Ducassou S, Corradini N, Bertozzi AI, Guérin E, Vincent F, Velten M, Entz-Werle N.
Jannier S, et al. Among authors: leblond p.
Cancers (Basel). 2020 Oct 20;12(10):3051. doi: 10.3390/cancers12103051.
Cancers (Basel). 2020.
PMID: 33092063
Free PMC article.